



## Bassil Dahiyat

Dr. Dahiyat has served as Xencor's president and chief executive officer since the Company's founding in 1997 and is a co-inventor of Xencor's breakthrough XmAb® technology. He has led the Company in raising over \$700 million in public and private financing, creating a diverse portfolio of monoclonal antibody clinical programs for the treatment of life-threatening and debilitating diseases, and establishing alliances with leading biopharmaceutical companies that generated over \$300 million in upfront payments. Dr. Dahiyat holds a Ph.D. in Chemistry from Caltech and B.S. and M.S.E. degrees in Biomedical Engineering from the Johns Hopkins University. He has co-authored numerous scientific papers in the fields of protein design and drug delivery, is an inventor of over 30 U.S. and numerous foreign patents and has received scientific awards from the American Chemical Society, the Controlled Release Society, the Protein Society and Caltech.